Low Leverage / Balance Sheet FlexibilityModest debt and a low debt-to-equity ratio reduce refinancing pressure and preserve financial flexibility for a pre-commercial biotech. This structural strength helps the company manage R&D spending and pursue partner deals or targeted financing over the next several months without immediate solvency risk.

Asset-centric Partnership StrategyA go-to-market approach focused on advancing proprietary candidates to partnering de-risks late-stage capital requirements. Structurally, licensing and collaboration models can provide milestone and development funding, allowing sustained R&D progress while limiting the need for immediate commercial infrastructure or large upfront capital.

CNS Specialization And Targeted PipelineConcentrated expertise in CNS and Alzheimer’s therapies builds domain knowledge and a clear clinical focus, which supports efficient trial design and partner interest. Over the medium term, specialization increases the likelihood of strategic collaborations in a high unmet-need area, preserving long-term commercialization optionality.

Bears Say

No Revenue And Widening Net LossesAn ongoing pre-revenue profile with materially widening losses indicates the company remains far from commercial cash generation. Persistent negative earnings erode equity and increase reliance on external funding, creating execution and dilution risk that could constrain R&D programs over the next several months.

Negative Operating And Free Cash FlowSustained negative operating and free cash flow show the company is burning cash to fund development. This structural cash consumption increases the probability of near-term financing needs, limits strategic optionality, and may force dilutive equity raises or slowed development pacing if external funding is constrained.

Equity Erosion And Funding RiskMaterial erosion of shareholders' equity reduces the balance sheet buffer against future losses and makes non-dilutive financing harder to secure. Continued capital erosion heightens the likelihood of dilution or asset monetization, which can impair long-term program continuity and shareholder value retention.

AC6 FAQ

What was AlzeCure Pharma AB’s price range in the past 12 months?

AlzeCure Pharma AB lowest stock price was €0.13 and its highest was €0.44 in the past 12 months.

What is AlzeCure Pharma AB’s market cap?

AlzeCure Pharma AB’s market cap is €20.41M.

When is AlzeCure Pharma AB’s upcoming earnings report date?

AlzeCure Pharma AB’s upcoming earnings report date is May 05, 2026 which is in 57 days.

How were AlzeCure Pharma AB’s earnings last quarter?

AlzeCure Pharma AB released its earnings results on Feb 26, 2026. The company reported -€0.014 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.014.

Is AlzeCure Pharma AB overvalued?

According to Wall Street analysts AlzeCure Pharma AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does AlzeCure Pharma AB pay dividends?

AlzeCure Pharma AB does not currently pay dividends.

What is AlzeCure Pharma AB’s EPS estimate?

AlzeCure Pharma AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does AlzeCure Pharma AB have?

AlzeCure Pharma AB has 114,914,450 shares outstanding.

What happened to AlzeCure Pharma AB’s price movement after its last earnings report?

AlzeCure Pharma AB reported an EPS of -€0.014 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.667%.

Which hedge fund is a major shareholder of AlzeCure Pharma AB?

Currently, no hedge funds are holding shares in DE:AC6

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

AlzeCure Pharma AB

AlzeCure Pharma AB (publ), a pharmaceutical company, develops drug therapies for the treatment of severe diseases and conditions that affect the central nervous system. The company is developing drug candidates based on the NeuroRestore, Alzstatin, and Painless research platforms. Its pipeline drug candidates include ACD856, which is in phase I clinical trial for Alzheimer's disease, sleep disorders, traumatic brain injuries, and Parkinson's disease; ACD857, ACD679, and ACD680 for Alzheimer's disease; ACD440, a TRPV1 antagonist that has completed phase I clinical trial for neuropathic pain; and TrkA-NAM for osteoarthritic pain. The company was founded in 2012 and is based in Huddinge, Sweden.